You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
創勝集團(06628.HK)治療胃癌藥物臨床顯示73.3%患者腫瘤呈現部分緩解
阿思達克 09-13 08:50
創勝集團-B(06628.HK)公布,在2022年歐洲腫瘤內科學會(ESMO)年會上,以壁報形式公布其具有增強ADCC活性的人源化抗Claudin18.2單克隆抗體TST001 (Osemitamab)聯合卡培他濱和奧沙利鉑(CAPOX)作為局部晚期或轉移性胃癌及胃食管連接部(G/GEJ)癌一線治療的I/II期臨床試驗中劑量擴展隊列研究的中期安全性和療效數據。 截至8月4日,共有51個患者入組並接受治療。首批接受TST001 (Osemitamab)聯合CAPOX作為晚期或轉移性胃癌及胃食管連接部癌一線治療的15個有可測量病灶患者的中期數據顯示,根據RECIST1.1標準,73.3%的患者腫瘤呈現部分緩解,疾病控制率高達100%。 積極的臨床結果進一步推進了TST001 (Osemitamab)項目進展,公司正向監管部門開展諮詢,為啟動TST001 (Osemitamab)一線治療局部晚期或轉移性Claudin18.2陽性胃癌及胃食管連接部癌的全球III期臨床試驗做準備。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account